Technology
Health
Pharmaceutical

Trevi Therapeutics

$4.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.24 (5.45%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell TRVI and other stocks, options, ETFs, and crypto commission-free!

About TRVI

Trevi Therapeutics, Inc. Common Stock, also called Trevi Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. Read More It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.

Employees
15
Headquarters
New Haven, Connecticut
Founded
2011
Market Cap
82.75M
Price-Earnings Ratio
Dividend Yield
Average Volume
7.33K
High Today
$4.65
Low Today
$4.42
Open Price
$4.52
Volume
9.37K
52 Week High
$10.62
52 Week Low
$4.04

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2019 IPO
US

TRVI Earnings

-$0.63
-$0.51
-$0.39
-$0.27
Q4 2018
Q1 2019
Estimated
Actual
-$0.63 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.